Renal Kallikrein-Kinin System and the Depressor Effect of Angiotensin Converting Enzyme Inhibitors MK 421, SA 446, And Captopril In Rats

References

• Abe K, Kato H, Sakurai Y, Ito T, Saito K, Haruyama T, Otsuka Y, Yoshinaga K. Estimation of urinary kininogenase activity using bovine serum low molecular weight kininogen, I I Kinin, S Fujii, H Moriya, T Suzuki. Plenum Publishing Corporation, New York 1979; p.105–114
   Google Scholar
• Bengis R G, Coleman T G, Young D B, McCaa R E. Long-term blockade of angiotensin formation in various normo-tensive and hypertensive rat models using converting enzyme inhibitor (SQ 14225). Circ Res 1978; 43(Suppl. 1)45–53
   Google Scholar
• Boyd G W, Landon J, Peart C S. Radioimmunoassay of angiotensin II. Proc Roy Soc (London) Series B: Biological Sciences 1969; 173: 327–338
   PubMed Web of Science ®Google Scholar
• Carretero O A, Oza N B, Piwonska A, Ocholik T, Scicli A G. Measurement of urinary kallikrein activity by kinin radioimmunoassay. Biochem Pharmacol 1976; 25: 2265–2270
   PubMed Web of Science ®Google Scholar
• Clappison B H, Anderson W P, Johnston C I. Renal hemodynamics and renal kinins after angiotensin converting enzyme inhibition. Kidney Int 1981; 20: 615–620
   PubMed Web of Science ®Google Scholar
• Dorer F E, Kahn J R, Lentz K E, Levine M, Skeggs L T. Hydrolysis of bradykinin by angiotensin-converting enzyme. Circ Res 1974; 34: 824–827
   PubMed Web of Science ®Google Scholar
• Erdös E G. Angiotensin converting enzyme. Circ Res 1975; 36: 247–255
   PubMed Web of Science ®Google Scholar
• Erdös E G. The angiotensin converting enzyme. Fed Proc 1977; 36: 1760–1765
   PubMedGoogle Scholar
• Gavras H, Brunner H R, Turini G A, Dershaw G R, Tifft C P, Cuttelod S, Gavras I, Vukovich R A, McKinstry D N. Antihypertensive effect of the oral angiotensin converting enzyme inhibitor SQ 14225 in man. N Eng J Med 1978; 298: 991–995
   PubMed Web of Science ®Google Scholar
• Hulthen L, Hokfelt B. The effect of the angiotensin converting enzyme inhibitor SQ 20881 on kinins renin-angiotensin-aldosterone and catecholamines in relation to blood pressure in hypertensive patients. Acta Med Scand 1978; 204: 497–502
   PubMed Web of Science ®Google Scholar
• Iso T, Yamauchi H, Suda H, Nakata K, Nishimura K, Iwao J. A new potent inhibitor of converting enzyme : (2R 4R)-2 - (2-hydroxyphenyl)-3-(3-mercaptopropionyl)-4-thi-azolidine-carboxylic acid (SA 446). Jap J Pharmacol 1981; 31: 875–882
   PubMedGoogle Scholar
• Johnston C I, Matthews P G, Dax E. Effects of dietary sodium, diuretics, and hypertension on renin and kalli-krein. Systemic effect of antihypertensive agents, M P Sambhi. Stratton Intercontinental, New York 1976; p.332–338
   Google Scholar
• Kauker M L. Bradykinin action on the efflux of luminal 22Na in the rat nephron. J Pharmacol Exp Ther 1980; 214: 119–123
   PubMed Web of Science ®Google Scholar
• Levinsky N G. The renal kallikrein-kinin system. Circ Res 1979; 44: 441–451
   PubMed Web of Science ®Google Scholar
• Margolius H S, Horwitz D, Pisano J J, Keiser H R. Urinary kallikrein excretion in normal man : relationships to sodium intake and sodium-retaining steroids. Circ Res 1974; 35: 812–819
   PubMed Web of Science ®Google Scholar
• Margolius H S, Pisano J J, Geller R, Sjoerdsma A. Altered urinary kallikrein excretion in human hypertension. Lancet 1971; 2: 1063–1065
   PubMed Web of Science ®Google Scholar
• Matthews P G, Johnston C I. Changes in endogenous angiotensin and bradykinin after inhibition of converting enzyme (kininase II). Med J Aust 1979; 21(Suppl. 2)12–14
   Google Scholar
• McCaa R E, Hall J E, McCaa C S. The effects of angiotensin I converting enzyme inhibitors on arterial blood pressure and urinary sodium excretion : role of the renal renin-angiotensin and kallikrein-kinin systems. Circ Res 1978; 43(Suppl. 1)32–39
   Google Scholar
• Merrill J E, Peach M J, Gilmore J P. Angiotensin I conversion in the kidney and its modulation by sodium balance. Am J Physiol 1973; 224: 1104–1108
   PubMed Web of Science ®Google Scholar
• Murthy V S, Waldron T L, Goldberg M E. The mechanism of bradykinin potentiation after inhibition of angiotensin-converting enzyme by SQ 14225 in conscious rabbits. Circ Res 1978; 43(Suppl. 1)40–45
   Google Scholar
• Ondetti M A, Rubin B, Cushman S W. Design of specific inhibitors of angiotensin converting enzyme : new class of orally active antihypertensive agents. Science 1977; 196: 441–443
   PubMed Web of Science ®Google Scholar
• Patchett A A, Harris E, Tristram E W, Wyvratt M J, Wu M T, Taub D, Peterson E R, Ikeler T J, Tenbroueke J, Payne L G, Ondevka D L, Thorsett E D, Greenlee E S, Lohn N S, Hoffsommer R D, Joshua H, Ruyle W V, Rothrock J W, Aster S D, Maycock A L, Robinson F M, Hirschmann R, Sweet C S, Ulm E H, Gross D M, Vassil T C, Stone C A. A new class of angiotensin-converting enzyme inhibitors. Nature 1980; 288: 280–283
   PubMed Web of Science ®Google Scholar
• Peart W S. A new method of large scale preparation of hypertension with a note on its assay. Biochem J 1955; 55: 300–304
   Google Scholar
• Rubin R, Laffan R F, Kotler D G, O'Keefe E H, Demaio D A, Goldberg M E. SQ 14225 (D-3-mercapto-2-methylpro-panoyl-L-proline) a novel orally active inhibitor of angiotensin I converting enzyme. J Pharmacol Exp Ther 1978; 204: 271–280
   PubMed Web of Science ®Google Scholar
• Swartz S L, Williams G H, Hollenberg N K, Moore T J, Dluhy R G. Converting enzyme inhibition in essential hypertension : the hypotensive response does not reflect only reduced angiotensin II formation. Hypertension 1979; 1: 106–111
   PubMed Web of Science ®Google Scholar
• Thurston H, Swales J D. Converting enzyme inhibitor and saralasin infusion in rats. Circ Res 1978; 42: 588–592
   PubMed Web of Science ®Google Scholar
• Turini G A, Gribic M, Brunner H R, Waever B, Gavras H. Improvement of chronic congestive heart failure by oral captopril. Lancet 1979; 1: 1213–1215
   PubMed Web of Science ®Google Scholar
• Yasujima M, Matthews P G, Johnston C I. Regulation of uterine smooth muscle bradykinin receptors by bradykinin levels and angiotensin converting enzyme inhibitors in the rat. Clin Exp Pharmacol Physiol 1981; 8: 515–518
   PubMed Web of Science ®Google Scholar
• Yasujima M, Matthews P G, Johnston C I. Decreased uterine bradykinin receptors during captopril infusion in rats. Am J Cardiol 1982; 49: 1518–1520
   PubMed Web of Science ®Google Scholar
• Zinner S H, Margolius H S, Rosmer B, Keiser H R, Kass E H. Familial aggregation of urinary kallikrein concentration in childhood. Am J Epidemiol 1976; 104: 124–132
   PubMed Web of Science ®Google Scholar